文献速递临床试验与 GCP真实世界研究与卫生经济

癌症低风险中性粒细胞减少性脓毒症患者早期静脉转口服抗生素治疗:EASI-SWITCH 随机对照试验研究方案

Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-05-27

EASI-SWITCH 是一项实用性、随机、非劣效性试验,旨在评估低风险中性粒细胞减少性脓毒症癌症患者早期从静脉转口服抗生素的临床与成本效果。计划纳入 230 例患者,主要终点为第 14 天治疗失败复合终点,非劣效界值 15%。

要点

  • 早期转口服或可替代长程静脉抗生素,需非劣效证据支持。
  • 入组需 MASCC 评分≥21 且静脉抗生素使用<24 小时。
  • 主要终点为第 14 天治疗失败复合终点。

核心结论

  • 若试验证实早期转口服非劣效,可能改变低风险中性粒细胞减少性脓毒症的常规管理。

研究设计与样本

  • 实用性、随机、非劣效性试验,计划招募 230 例患者。
  • 纳入≥16 岁、接受系统性抗癌治疗(急性白血病/干细胞移植除外)、体温>38°C、中性粒细胞≤1.0×10^9/L、MASCC 评分≥21 且静脉抗生素使用<24 小时的患者。

主要发现

  • 原文未报告试验结果,仅描述研究方案。

关键数值与推荐

  • 干预组在开始静脉抗生素后 12-24 小时内转为口服环丙沙星和阿莫西林/克拉维酸,总抗生素疗程至少 5 天。
  • 对照组继续静脉抗生素至少 48 小时,后续由医生决定。
  • 主要终点为第 14 天治疗失败复合终点,包括开始静脉抗生素 72 小时后发热持续或复发、方案抗生素升级、感染/抗生素相关再入院、重症监护支持或死亡。
  • 假设对照组治疗失败率 15%,非劣效界值 15%。

临床怎么用

  • 对于符合低风险标准的中性粒细胞减少性脓毒症癌症患者,早期转口服策略可能减少静脉抗生素使用时间和住院资源。

局限性

  • 原文未报告试验结果,无法评估干预的实际效果与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neutropenic sepsis remains a common treatment complication for patients receiving systemic anti-cancer treatment. The UK National Institute for Health and Care Excellence have not recommended switching from empirical intravenous antibiotics to oral antibiotics within 48 h for patients assessed as low risk for septic complications because of uncertainty about whether this would achieve comparable outcomes to using intravenous antibiotics for longer. The UK National Institute for Health Research funded the EASI-SWITCH trial to tackle this uncertainty. METHODS: The trial is a pragmatic, randomised, non-inferiority trial that aims to establish the clinical and cost-effectiveness of early switching from intravenous to oral antibiotics in cancer patients with low-risk neutropenic sepsis. Patients ≥ 16 years, receiving systemic anti-cancer treatment (acute leukaemics/stem cell transplants excluded), with a temperature of > 38 °C, neutrophil count ≤ 1.0 × 109/L, MASCC (Multinational Association of Supportive Care in Cancer) score ≥ 21 and receiving IV piperacillin/tazobactam or meropenem for less than 24 h are eligible to participate. Patients are randomised 1:1 either (i) to switch to oral ciprofloxacin and co-amoxiclav within 12-24 h of commencing intravenous antibiotics, completing at least 5 days total antibiotics (intervention), or (ii) to continue intravenous antibiotics for at least 48 h, with ongoing antibiotics being continued at the physician's discretion (control). Patients are discharged home when their physician deems it appropriate. The primary outcome measure is a composite of treatment failures as assessed at day 14. The criteria for treatment failure include fever persistence or recurrence 72 h after starting intravenous antibiotics, escalation from protocolised antibiotics, hospital readmission related to infection/antibiotics, critical care support or death. Based on a 15% treatment failure rate in the control group and a 15% non-inferiority margin, the recruitment target is 230 patients. DISCUSSION: If the trial demonstrates non-inferiority of early switching to oral antibiotics, with potential benefits for patient quality of life and resource savings, this finding will have significant implications for the routine clinical management of those with low-risk neutropenic sepsis. TRIAL REGISTRATION: ISRCTN: 84288963. Registered on the 1 July 2015. https://doi.org/10.1186/ISRCTN84288963. EudraCT: 2015-002830-35.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Forde C, McMullan R, Clarke M, et al. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. Trials. 2020. PMID: 32460818. doi:10.1186/s13063-020-04241-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。